TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04727151

Recruitment Status : Active, not recruiting

First Posted : January 27, 2021

Last Update Posted : February 9, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Merck Sharp & Dohme LLC

Information provided by (Responsible Party):

Triumvira Immunologics, Inc.

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	June 2025
Estimated Study Completion Date :	June 2027

To Top